USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
THERASOURCE, LLC
Address:
59 HIGHLAND AVE
ROSLYN, NY 11576-2011
EIN:
202618814
DUNS:
144994972
Number of Employees:
12
Woman-Owned?:
No
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,371,442.00 7
SBIR Phase II $7,647,884.00 6

Award List:

A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$299,990.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Trauma causes approximately 150,000 deaths per year, and is the leading cause of death in the population between ages 1 to 44 in the United States. The resulting loss of productive life years exceeds that of any other disease, with estimated societal costs of… More

Treatment of Surgical Sepsis with AM/AMBP-1

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$146,002.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sepsis continues to be the most common cause of death in surgical intensive care units. Despite advances in the management of trauma victims, the incidence of sepsis and septic shock has increased significantly. More than 750,000 patients develop severe sepsis… More

New Therapy for Bowel Ischemia-Reperfusion Injury

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$302,970.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Acute mesenteric ischemia is an abdominal emergency with a mortality rate of up to 60-80%. Even though numerous modalities and substances have been studied to reduce gut ischemia/reperfusion (I/R)-induced mortality, none have been entirely successful. As such,… More

A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,485,053.00
Agency:
HHS
Principal Investigator:
Abstract:
Not avaiable.

Treatment of Surgical Sepsis with AM/AMBP-1

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,302,414.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase II proposal is a plan to further develop a new therapeutic approach that will save the lives of patients with sepsis (especially surgical sepsis), a condition that affects 750,000 people every year in th e United States alone and also causes high… More

Antagonism of Alpha2A-Adrenoceptor: A Novel Anti-Sepsis Therapy

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$197,522.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase I proposal is intended to demonstrate the feasibility of further development of a novel therapy for patients with sepsis through the modulation of cytokine production. Sepsis is a leading cause of death in non-cardiac intensive care units.… More

A Novel Therapy for Septic Shock

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$429,458.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase I/Phase II Fast-Track proposal is intended to develop a novel therapy for patients with sepsis and septic shock. Septic shock is the leading cause of death in non-cardiac intensive care units. Despite ad vances in the management of trauma victims,… More

A Novel Therapeutic Approach for Liver Injury

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$399,848.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Liver injury induced by hepatic ischemia and reperfusion (I/R) is a major cause of liver failure after severe trauma, thermal injury, hemorrhagic and septic shock, liver resection, or liver transplantation. Hepatic I/R contributes significantly to multiple organ… More

A Novel Therapy for Septic Shock

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,599,633.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase I/Phase II Fast-Track proposal is intended to develop a novel therapy for patients with sepsis and septic shock. Septic shock is the leading cause of death in non-cardiac intensive care units. Despite ad vances in the management of trauma victims,… More

A New Therapy for Bowel Ischemia-Reperfusion Injury

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,228,356.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The purpose of this SBIR Phase II proposal is to further develop a novel treatment that will be used to save the lives of patients with intestinal ischemia/reperfusion (I/R) injury. Although various modalities and subst ances have been studied to reduce… More

Human Ghrelin As An Effective Mitigator of Acute Radiation Injury

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$595,652.00
Agency:
HHS
Principal Investigator:
Weng-lang Yang – 516-562-1370
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase I proposal is intended to demonstrate the feasibility of developing a novel and effective therapeutic approach that can save lives of people with radiation injury. Acute radiation injury may occur in various incidents as well as the terrorist… More

Antagonism of Alpha2A-Adrenoceptor: A Novel Anti-Sepsis Therapy

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,561,899.00
Agency:
HHS
Principal Investigator:
Xiaoling Qiang – 516-562-1370
Abstract:
DESCRIPTION (provided by applicant): This SBIR Phase II proposal is a plan to further develop a novel therapeutic approach that will save the lives of patients with sepsis. Despite the increased understanding of the complex pathophysiology of sepsis, severe sepsis still results in significant… More

IGF;;OT;;IGF This SBIR phase II, contract is targeted towards completing the prec

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$470,529.00
Agency:
HHS
Principal Investigator:
Wayne Chaung – 516-641-0196
Abstract:
Despite advances in our understanding of excessive alcohol intake-related tissue injury, high morbidity and mortality due to infections in alcohol abusers remain a prominent challenge. Milk fat globule epidermal growth factor-factor VIII (MFG-E8) is involved in the clearance of apoptotic cells. We… More